| |
"Clinical Trials in Russia”, summary by EA, August 2011 |
| |
Russia is one of the most attractive regions to conduct clinical trials. There are several advantages to place clinical trials in this area:
- Population size of 141,8 million, providing access to a large potential pool of mostly treatment naive clinical trial subjects
- Centralized healthcare system with the developed referral network and a number of private practices. As a result - few sites needed to get a large number of patients
- Good selection of high-quality investigational sites
- ICH-GCP compliance principles incorporated into legislation
- High recruitment rates with low drop-out rates: Patient recruitment rates in the region is up to 10 times higher than in US and EU
- Savings in costs: Average cost per patient in Eastern Europe is 28% lower than in Western Europe and 47% than in the UK
- Possibility to reduce clinical trial expenditure by using local CROs and labs
- High qualification level of investigators for conducting clinical trials. All of the investigators are medical doctors; many speak English fluently, attend international conferences, and are members of European and American professional societies. Clinicians are GCP experienced. Over 60% of clinical investigators have PhD credentials with some 40% of them teaching at major universities.
|
|
|
|
| "Biosimilar Strategy & 351K", by D. A. Prasanna, at 'CPhI 2014, Paris 2014 |
|
|
|
| “Stemcell to Market faster”, by D. A. Prasanna, at ‘IsraStem 2013’, Tel Aviv 2013 |
|
|
|
| “Cell Therapy Trials - How CROs can impact trial outcome” by Dr. S. Kher at Stemcell Symposium, Tel Aviv 2013 |
|
|
|
| “Speed to Dermatology Market and Clinical Endpoint studies“ by D.A. Prasanna & Nurjehan Jivani at BA&BE; conference, Mumbai, December 2012 |
|
|
|
| "World’s First Approved Stem Cell Drug“ – May 2012 |
|
|
|
| "Stem cell therapy clinical development capabilities“ by D A Prasanna, London, March 2010 |
|
| |
|
| |
Read this whitepaper in PDF format  |
| |
|
|
|